# HIK.L - Hikma Pharmaceuticals PLC

> Analysis Date: 2026-02-04
> Framework: v3.0 (Quality First)
> Analyst: Claude (Fundamental Analyst Agent)

---

## TL;DR

Hikma Pharmaceuticals es un fabricante de genericos e inyectables con fuerte posicion en MENA (#2) y US (#3 en injectables, #7 en generics). Quality Score 46/100 (Tier C) indica que es un **Special Situation** - solo atractiva si hay catalyst claro. El CEO renuncio inesperadamente en diciembre 2025 causando la caida a 3-year low, pero la familia fundadora (30.9% insider ownership) retomo el control. Valuacion P/E 13.4x, EV/EBITDA 6.3x es razonable pero no excepcional. **MoS actual 23% vs base case no cumple el 30-40% requerido para Tier C.** Necesita catalyst adicional o precio mas bajo para BUY.

---

## Quality Score: 46/100 -> Tier C

### Breakdown Detallado

#### FINANCIAL QUALITY: 21/40

| Metrica | Valor | Puntos | Comentario |
|---------|-------|--------|------------|
| ROIC Spread (ROIC - WACC) | +1.1pp | 4/15 | ROIC ~9%, WACC ~8%. Apenas genera valor sobre coste de capital |
| FCF Margin | 10.5% | 5/10 | FCF $329M / Revenue $3.13B = 10.5%. Aceptable |
| Leverage (ND/EBITDA) | 1.7x | 8/10 | Net Debt $1.32B / EBITDA $764M. Conservative |
| FCF Consistency | 4/5 anos | 4/5 | FCF positivo 2021-2024 excepto 2025 H1 (timing capex) |

#### GROWTH QUALITY: 5/25

| Metrica | Valor | Puntos | Comentario |
|---------|-------|--------|------------|
| Revenue CAGR 5yr | 5.2% | 5/10 | Modesto crecimiento organico |
| EPS CAGR 5yr | -2.9% | 0/10 | EPS volatil (2021: $421M, 2023: $190M, 2024: $359M) |
| Gross Margin Trend | Declining | 0/5 | GM bajo vs sector pharma median (43% vs 67%) |

#### MOAT EVIDENCE: 10/25

| Metrica | Valor | Puntos | Comentario |
|---------|-------|--------|------------|
| GM Premium vs Sector | -12pp | 0/10 | GM 43% vs Pharma median 67%. Generics = low margin |
| Market Position | #3-7 | 5/8 | #3 US injectables, #7 US generics, #2 MENA |
| ROIC Persistence | ~5-6/10yr | 5/7 | ROIC marginal en anos recientes |

#### CAPITAL ALLOCATION: 10/10

| Metrica | Valor | Puntos | Comentario |
|---------|-------|--------|------------|
| Shareholder Returns | 10+ anos | 5/5 | Dividendo pagado consistentemente desde IPO 2005 |
| Insider Ownership | 30.9% | 5/5 | Familia Darwazah controla ~30%. Skin in the game |

### TIER C: SPECIAL SITUATION

- MoS Requerido: **30-40%**
- MoS Actual vs Base: **23%** -> NO CUMPLE
- Accion: Solo considerar si hay catalyst claro

---

## Business Understanding

### Modelo de Negocio

Hikma opera 3 segmentos:

1. **Injectables (42% revenue, ~30% margin)**: Medicamentos esteriles inyectables para hospitales. Top 3 en US con >150 moleculas. Alta barrera de entrada (sterile manufacturing requiere facilities especializadas FDA-approved).

2. **Generics (33% revenue, ~16% margin)**: Oral solids, nasal sprays, genericos complejos para mercado US. #7 por volumen. Mercado muy competitivo, pricing pressure constante.

3. **Branded (25% revenue, ~25% margin)**: Genericos de marca y productos in-licensed para mercado MENA. #2 en region. Menor competencia pero mercado mas pequeno.

**Problema que resuelve**: Provee medicamentos esenciales a hospitales (injectables) y farmacias (generics) a precios accesibles vs branded drugs.

**Modelo de ingresos**: Transaccional/Consumibles - ventas repetidas de medicamentos a hospitales, distribuidores y farmacias.

### Unit Economics

| Metrica | Valor | Comentario |
|---------|-------|------------|
| Gross Margin | 43% | Inferior a pharma innovador (67%), tipico de generics |
| Operating Margin | 22.6% | Razonable para manufacturing |
| FCF Margin | 10.5% | Aceptable |
| FCF Conversion | ~90% | Buen conversion de net income a FCF |
| Capex/Revenue | ~8% | Medium capital intensity |

**Capital Intensity**: Media-Alta. Plantas de manufactura esteril son capex-intensive pero duraderas.

### Por Que Esta Barata

**Narrativa del Mercado**:
1. [X] CEO renuncio inesperadamente (Dic 2025) - Riad Mishlawi out, Said Darwazah (Chairman/founder) retomo control
2. [X] Guidance reducido - Revenue CAGR 2024-2027 rebajado a "lower end of 6-8%", Operating profit 5-7% (vs 7-9%)
3. [X] Bedford facility delay - Full operation pushed to end 2027 (was 2026)
4. [X] Margen pressure en H1 2025 (-7% core operating profit)
5. [X] Barclays downgrade to Underweight (Jan 2026)
6. [X] Sector out-of-favor - Pharma/generics con sentiment negativo

**Mi Contra-Tesis**:

| Mercado Cree | Yo Creo | Evidencia | Prob Equivocado |
|--------------|---------|-----------|-----------------|
| CEO exit = problemas ocultos | Familia fundadora retoma control = alignment | 30.9% insider ownership, Darwazah fundador | 35% |
| Guidance cut = deterioro | Guidance es conservador, management siempre cautious | Historico de beats | 40% |
| Bedford delay = execution issues | Capex investment = capacity expansion para growth | $1B investment plan para US generics | 30% |
| Generic margins comprimiendo | Injectables mantiene 30% margin, es business principal | Injectables margin stable 5yr | 25% |

**Value Trap Checklist**: 3/10 factores

| Factor | SI/NO | Comentario |
|--------|-------|------------|
| Industria en declive secular | NO | Pharma creciendo 6% CAGR |
| Disrupcion tecnologica inminente | NO | Manufacturing esteril dificil de disrumpir |
| Management destruyendo valor | NO | Family ownership alineado |
| Balance deteriorandose | NO | Leverage conservador 1.7x |
| Insider selling masivo | NO | Familia COMPRANDO acciones (Aug 2025) |
| Dividend cut reciente | NO | Dividendo estable |
| Perdida market share >2pp | PARCIAL | US generics competitivo |
| ROIC < WACC ultimos 3 anos | PARCIAL | ROIC spread muy bajo |
| FCF negativo >2 anos | NO | FCF positivo |
| Goodwill >50% equity | PARCIAL | Goodwill significativo de M&A historico |

**TOTAL: 3/10** -> Tier C minimo (MoS 30%+ requerido)

### Ventaja Informacional

- [X] Horizonte temporal mas largo (family ownership = patient capital)
- [X] Mercado sobre-reacciona a CEO exit
- [ ] Entiendo negocio mejor - Solo parcialmente, generics es commoditizado
- [ ] Ninguna clara -> CAUTELA EXTREMA aplicada

---

## Catalysts y Timeframe

### Catalysts Identificados

| Catalyst | Timeframe | Prob | Impacto |
|----------|-----------|------|---------|
| FY2025 results beat (26-Feb-2026) | <1 mes | Medium | +10-15% |
| New CEO appointment | 6-12m | High | +5-10% (reduces uncertainty) |
| Bedford fully operational | End 2027 | High | +10% (unlocks capacity) |
| Biosimilar launches US | 2026-2027 | Medium | +5-10% |
| M&A target (family may sell) | 12-24m | Low | +20-30% premium |

### Que Tiene Que Pasar

1. Management estabiliza guidance post-CEO transition
2. Injectables margin se mantiene >28%
3. Bedford investment generates expected returns (ROIC >12%)

### Kill Conditions (OBLIGATORIO)

1. **Injectables operating margin <25%** durante 2 trimestres consecutivos
2. **Familia Darwazah vende shares** (>5% del stake)
3. **Dividend cut o suspension**
4. **Net debt >2.5x EBITDA**
5. **US generics business vendido o restructurado** (core business abandonado)

---

## Proyeccion Framework

### TAM Analysis

| Mercado | TAM 2025 | CAGR | Hikma Share |
|---------|----------|------|-------------|
| Global Generics | $400B | 5.5% | <1% |
| US Generics | $130B | 4% | ~1% |
| US Injectables | $40B | 6% | ~3% |
| MENA Pharma | $50B | 7% | ~2% |

**TAM Growth**: 5-6% (weighted)

### Market Share Trend

- US Injectables: Stable (#3 position, 150+ molecules)
- US Generics: Modestly declining (commoditization)
- MENA: Expanding (manufacturing investments)

### Revenue Projection Formula

```
Revenue Growth = TAM Growth (5%) + dShare (0%) + Pricing (-1%) = 4%
Guidance: 4-6% revenue growth
My estimate: 4-5% (conservative)
```

### WACC Derivation

```
Risk-Free Rate (UK 10Y): 4.0%
Equity Risk Premium: 5.0%
Beta: 0.71
Cost of Equity (Ke) = 4.0% + 0.71 * 5.0% = 7.55%

Cost of Debt: 5.0% (estimated)
Tax Rate: 23%
Kd after-tax = 5.0% * (1-0.23) = 3.85%

Capital Structure:
- Market Cap: GBP 3.61B (~USD 4.5B)
- Net Debt: GBP 1.32B (~USD 1.65B)
- E/V: 73%
- D/V: 27%

WACC = (73% * 7.55%) + (27% * 3.85%) = 6.55%
Use 7% for conservatism
```

---

## Valoracion Multi-Metodo (Tier B/C: DCF + EV/EBIT)

### Metodo 1: DCF (60% peso)

**Tool output (python3 tools/dcf_calculator.py HIK.L --scenarios)**:

| Escenario | Fair Value (GBp) | MoS vs Current 1632p |
|-----------|------------------|----------------------|
| Bear | 1477 | -9.5% (DOWNSIDE) |
| Base | 2011 | +23.2% |
| Bull | 2768 | +69.6% |

**Parametros DCF Tool**:
- Growth: 5% base (tool default)
- WACC: 9% (tool default, conservativo vs mi 7%)
- Terminal: 2.5%

**Ajuste con mi WACC 7%**:

Con WACC 7%, DCF seria significativamente mayor. Usando tool defaults es conservador.

### Metodo 2: EV/EBIT Normalizado (40% peso)

**Calculo**:
```
EBIT TTM: ~$600M (Operating Income)
EBIT Normalizado (5yr avg): ~$580M
EV/EBIT Actual: 4.78B / 0.48B = 10.0x (GBP)

Sector Pharma EV/EBIT: 10-14x
Peer Generics: 8-10x

Target Multiple: 9x (below sector due to generics/growth)
Fair Value EV: $580M * 9 = $5.22B
Less Net Debt: $1.65B
Equity Value: $3.57B
Per Share: ~1980 GBp
```

### Reconciliacion

| Metodo | Fair Value (GBp) | Peso | Weighted |
|--------|------------------|------|----------|
| DCF Base | 2011 | 60% | 1207 |
| EV/EBIT 9x | 1980 | 40% | 792 |
| **Weighted Avg** | | 100% | **1999 GBp** |

**Precio actual: 1632 GBp**
**MoS vs Weighted FV: 18%**
**MoS vs Bear Case: -9.5% (NEGATIVO)**

---

## Escenarios Bear/Base/Bull

| Escenario | Prob | Assumptions | FV (GBp) |
|-----------|------|-------------|----------|
| **Bear** | 25% | Revenue flat, margin compression 200bp, WACC +1% | 1477 |
| **Base** | 50% | Revenue +4-5%, margins stable, WACC 9% | 2011 |
| **Bull** | 25% | Revenue +7%, Bedford delivers, WACC -1%, M&A premium | 2768 |

**Expected Value = (1477 * 0.25) + (2011 * 0.50) + (2768 * 0.25) = 2067 GBp**

**MoS vs Expected Value: (2067-1632)/2067 = 21%**
**MoS vs Bear: (1477-1632)/1477 = -10.5% (DOWNSIDE)**

---

## Assessment Final

### MoS Analysis

| Metrica | Valor | Requerido | Cumple? |
|---------|-------|-----------|---------|
| Quality Score | 46/100 | - | Tier C |
| MoS Base Requerido | 30-40% | 30% min | - |
| MoS vs Base Case | 23% | 30% | **NO** |
| MoS vs Bear Case | -10% | >0% | **NO** |
| MoS vs Expected Value | 21% | 30% | **NO** |

### Value vs Value Trap Analysis

**Factores Positivos**:
1. Family ownership (30.9%) - alineamiento con shareholders
2. Insider BUYING not selling (Aug 2025)
3. Conservative leverage (1.7x)
4. Dividendo estable, yield 4.1%
5. Injectables position defensible (#3 US)
6. MENA expansion en progreso

**Factores Negativos**:
1. Low ROIC spread (apenas >WACC)
2. Generics is commoditized business
3. Management transition uncertainty
4. Gross margin below sector median
5. EPS volatility (no consistent growth)
6. MoS insuficiente para Tier C

### 8 Gates Check

| Gate | Status | Comentario |
|------|--------|------------|
| G1: Quality Score | PASS | 46/100 = Tier C |
| G2: Business Understanding | PASS | Modelo entendido |
| G3: Proyeccion Fundamentada | PASS | Growth derivado |
| G4: Valoracion Multi-Metodo | PASS | DCF + EV/EBIT |
| G5: Margen de Seguridad | **FAIL** | 23% < 30% requerido |
| G6: Contexto Macro | PASS | Pharma defensive |
| G7: Portfolio Fit | PASS | Healthcare 4.3% < 10-15% target |
| G8: Autocritica | PASS | Value trap score 3/10, documented |

**RESULTADO: GATE 5 FAIL - MoS INSUFICIENTE**

---

## Veredicto: WATCHLIST (No BUY)

### Razon

Hikma es un negocio decente pero no excepcional (Tier C, QS 46). Para comprar un Tier C, necesito MoS 30-40% y un catalyst claro. Actualmente:

- MoS 23% < 30% requerido
- Bear case tiene DOWNSIDE 10.5%
- CEO transition crea uncertainty a corto plazo

### Entry Price para BUY

Para alcanzar MoS 30%:
```
Entry = Fair Value * (1 - MoS)
Entry = 2011 * 0.70 = 1408 GBp
Current: 1632 GBp
Necesita caer: -14% adicional
```

**Standing Order Price: 1400-1450 GBp**

### Cuando Reconsiderar

1. Precio cae a 1400-1450 GBp (MoS >30%)
2. FY2025 results (26-Feb) muestran estabilizacion/beat
3. Nuevo CEO nombrado con track record
4. Familia Darwazah aumenta stake materialmente

---

## Conexion Macro

### Sensibilidad

| Factor | Sensibilidad | Impacto Actual |
|--------|--------------|----------------|
| Tasas de interes | Baja | Defensivo |
| Recesion | Baja | Pharma es necesidad |
| Inflacion | Media | Pricing power limitado en generics |
| USD strength | Media | Revenue USD, costs mixed |
| Geopolitica MENA | Media | 25% revenue MENA |

### Fit con World View

De world/current_view.md:
- Pharma/Healthcare: "Neutral - buscar especificas infravaloradas"
- Hikma no esta entre odiados extremos (auto EU, energia)
- Valuacion no es "min historicos" como otros sectores

**Conclusion Macro**: Neutral. No hay viento de cola ni adverso fuerte. La oportunidad es company-specific (CEO transition, Bedford delay) no macro-driven.

---

## Meta-Reflection

### Dudas/Incertidumbres

1. **ROIC real vs estimado**: Calcule ROIC ~9% pero datos de yfinance pueden ser imprecisos. La company no reporta ROIC explicito.

2. **Goodwill quality**: Hikma ha hecho M&A historico. El goodwill podria estar impaired si generics margins siguen comprimiendo.

3. **Bedford investment returns**: Management dice generara crecimiento pero no cuantifico ROIC expected. Podria ser capex destructivo.

### Sugerencias de Mejora

1. **Quality Scorer tool** deberia dar mas detalle sobre sources de datos cuando hay discrepancias (ej: dividend yield 409% de yfinance es claramente error).

2. **Comparables automaticos**: Un tool que compare automaticamente vs peers (Teva, Sandoz) seria util para EV/EBIT relativo.

### Anomalias Detectadas

1. yfinance muestra Dividend Yield 409% y P/B 194.68 - claramente errores de data. Use price_checker que muestra yield 4.1% correcto.

2. El tool quality_scorer muestra gross margin declining pero el company reports GM estable ~43%. Verificar fuente.

### Preguntas para Orchestrator

1. Dado que tenemos PFE, SAN.PA, UHS en healthcare ya, y Hikma es Tier C con MoS insuficiente, deberiamos priorizar otras oportunidades en sectors con menos exposicion actual?

---

## Sources

- [Hikma Investor Relations](https://www.hikma.com/investors/)
- [Hikma 2025 Guidance Update](https://www.hikma.com/news/hikma-confirms-2025-guidance-and-updates-medium-term-growth-outlook/)
- [CEO Departure Announcement](https://www.hikma.com/news/hikma-announces-ceo-change-and-board-appointment/)
- [Yahoo Finance HIK.L Analysis](https://finance.yahoo.com/quote/HIK.L/analysis/)
- [MarketBeat Price Targets](https://www.marketbeat.com/stocks/LON/HIK/forecast/)
- [Investing.com Analyst Coverage](https://www.investing.com/equities/hikma-pharmaceuticals-consensus-estimates)
